Molecular Templates Shares Are Trading Higher After the Company Announced That It Will Present Interim Data From Its MT-6402 Phase I Study in Patients With PD-L1+ Solid Tumors at the 2024 AACR Annual Meeting
在該公司宣佈將在2024年AACR年會上公佈其針對PD-L1+實體瘤患者的 MT-6402 I 期研究的中期數據後,分子模板股價走高